The release kinetics of the cardiac specific troponin T (cTnT), measured by an immunosorbent assay, in 32 patients with acute myocardial infarction (AMI) was evaluated. In 8 AMI patients (25%), the release kinetics of...The release kinetics of the cardiac specific troponin T (cTnT), measured by an immunosorbent assay, in 32 patients with acute myocardial infarction (AMI) was evaluated. In 8 AMI patients (25%), the release kinetics of serum cTnT showed biphasic serum concentration curves with a large peak at 10 to 18 hours after onset and the serum cTnT concentrations were up to 30 to 120 times of the normal upper limit-detected (0.2 μg / ml), and another samll cTnT peak at 70 to 100 hours after onset of pain. The serum cTnT measurements in the remaining 24 AMI patients (75%) gave only one large peak which was around 32 to 108 hours after onset of pain. cTnT appeared in serum as early as 3 to 4 hours and remained elevated until 240 hours after the infarctions. The results indicated that (1) cTnT was a sensitive and specific marker of AMI; (2) the biphasic curve of cTnT releae in general, the ratio of cTnT at around 14 to 32 (14/32)>1 in particular, may be a useful marker suggesting early reperfusion; (3) the continuous elevation of serum cTnT in AMI course might be a prognostic indicator for unfavorable outcomes.展开更多
Objective To assess the prognostic significance of serum cardiac troponin I (cTnI) concentration in patients with acute myocardial infarction on admission. Methods Serum samples of 108 patients with established AMI ...Objective To assess the prognostic significance of serum cardiac troponin I (cTnI) concentration in patients with acute myocardial infarction on admission. Methods Serum samples of 108 patients with established AMI were collected on admission for measuring cTnI and were grouped according to the intervals between the onset of chest pain and admission. Results In each of these groups, the serum cTnI concentrations in patients died after admission were significantly higher than those who survived (all P<0.05). Conclusions A higher serum cTnI concentration on admission in patients with AMI was associated with an increased risk of subsequent cardiac death during hospitalization.展开更多
目的研讨Hs-cTnT、BNP水平与ACS患者住院转归的相关性。方法选取曲靖市第一人民医院2022年1月-2022年12月收住的ACS患者1185例作为研究组,选取同期收住的1000名非器质性心脏病患者作为对照组。采集患者基线资料和临床转归情况,对比2组...目的研讨Hs-cTnT、BNP水平与ACS患者住院转归的相关性。方法选取曲靖市第一人民医院2022年1月-2022年12月收住的ACS患者1185例作为研究组,选取同期收住的1000名非器质性心脏病患者作为对照组。采集患者基线资料和临床转归情况,对比2组患者血清Hs-cTnT、BNP测值的差异。结果研究组Hs-cTnT、BNP测值均高于对照组(0.07±0.01 VS 51.12±3.21,P<0.05);研究组中不稳定心绞痛、ST段抬高心梗、非ST段抬高心梗三个亚组间临床不良转归与血清BNP测值存在相关性(1%VS 1%VS 1%,P<0.05)。Hs-cTnT测值在ST段抬高心肌梗死与非ST段抬高心肌梗死预后理想与预后不理想亚组间存在相关性(0.023 VS 0.009,P<0.05);而不稳定心绞痛预后理想与预后不理想组间血清Hs-cTnT测值无显著性差异(0.062,P>0.05)。结论血清Hs-cTnT、BNP对ACS患者的疾病严重程度、预后转归具有良好的预测价值,两者联合应用价值更高,血清BNP测值的转归预测价值更高。展开更多
目的:观察益气通络化痰方联合达格列净治疗急性心肌梗死后心力衰竭的疗效及对心功能、血清脑钠肽(BNP)、心肌肌钙蛋白l(cTnl)水平的影响,以期为临床治疗提供可靠参考。方法:按照纳入和排除标准选用因急性心肌梗死入院时或住院期间出现...目的:观察益气通络化痰方联合达格列净治疗急性心肌梗死后心力衰竭的疗效及对心功能、血清脑钠肽(BNP)、心肌肌钙蛋白l(cTnl)水平的影响,以期为临床治疗提供可靠参考。方法:按照纳入和排除标准选用因急性心肌梗死入院时或住院期间出现心力衰竭的104例患者为研究对象,采集时间为2022年9月~2023年9月,按照随机数字表法将上述患者随机分为两组,即实验组与对照组,每组52例,其中对照组患者标准心力衰竭治疗(达格列净),实验组在标准治疗上加用益气通络化痰方。比较2组疗效,对其中医证候积分、心功能指标[心排出量(CO)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、血清指标[心房钠尿肽(ANP)、BNP、cTnl]的变化,并记录两组用药安全性及预后情况。结果:实验组总有效率为96.15%,而对照组总有效率为82.69%,两组相比差异有统计学意义( P <0.05);治疗后两组中医证候各项积分均较治疗前有不同程度的升高或降低( P <0.05),且治疗后相比,实验组LVESD、ANP、BNP、cTnl低于对照组( P <0.05),CO、LVEF、LVEDD高于对照组( P <0.05);实验组不良反应总发生率及因心衰再住院率分别为11.54%、5.77%,对照组分别为19.23%、19.23%,两组不良反应总发生率比较差异无统计学意义( P >0.05),但因心衰再住院率相比,差异有统计学意义( P <0.05)。结论:中医益气通络化痰方药联合达格列净用于急性心肌梗死后心力衰竭患者中疗效确切,不仅能有效恢复患者心功能作用,改善心室重构,还能调节ANP、BNP、cTnl等水平,抑制疾病进展,且预后良好,具有较大的临床应用价值。展开更多
文摘The release kinetics of the cardiac specific troponin T (cTnT), measured by an immunosorbent assay, in 32 patients with acute myocardial infarction (AMI) was evaluated. In 8 AMI patients (25%), the release kinetics of serum cTnT showed biphasic serum concentration curves with a large peak at 10 to 18 hours after onset and the serum cTnT concentrations were up to 30 to 120 times of the normal upper limit-detected (0.2 μg / ml), and another samll cTnT peak at 70 to 100 hours after onset of pain. The serum cTnT measurements in the remaining 24 AMI patients (75%) gave only one large peak which was around 32 to 108 hours after onset of pain. cTnT appeared in serum as early as 3 to 4 hours and remained elevated until 240 hours after the infarctions. The results indicated that (1) cTnT was a sensitive and specific marker of AMI; (2) the biphasic curve of cTnT releae in general, the ratio of cTnT at around 14 to 32 (14/32)>1 in particular, may be a useful marker suggesting early reperfusion; (3) the continuous elevation of serum cTnT in AMI course might be a prognostic indicator for unfavorable outcomes.
文摘Objective To assess the prognostic significance of serum cardiac troponin I (cTnI) concentration in patients with acute myocardial infarction on admission. Methods Serum samples of 108 patients with established AMI were collected on admission for measuring cTnI and were grouped according to the intervals between the onset of chest pain and admission. Results In each of these groups, the serum cTnI concentrations in patients died after admission were significantly higher than those who survived (all P<0.05). Conclusions A higher serum cTnI concentration on admission in patients with AMI was associated with an increased risk of subsequent cardiac death during hospitalization.
文摘目的研讨Hs-cTnT、BNP水平与ACS患者住院转归的相关性。方法选取曲靖市第一人民医院2022年1月-2022年12月收住的ACS患者1185例作为研究组,选取同期收住的1000名非器质性心脏病患者作为对照组。采集患者基线资料和临床转归情况,对比2组患者血清Hs-cTnT、BNP测值的差异。结果研究组Hs-cTnT、BNP测值均高于对照组(0.07±0.01 VS 51.12±3.21,P<0.05);研究组中不稳定心绞痛、ST段抬高心梗、非ST段抬高心梗三个亚组间临床不良转归与血清BNP测值存在相关性(1%VS 1%VS 1%,P<0.05)。Hs-cTnT测值在ST段抬高心肌梗死与非ST段抬高心肌梗死预后理想与预后不理想亚组间存在相关性(0.023 VS 0.009,P<0.05);而不稳定心绞痛预后理想与预后不理想组间血清Hs-cTnT测值无显著性差异(0.062,P>0.05)。结论血清Hs-cTnT、BNP对ACS患者的疾病严重程度、预后转归具有良好的预测价值,两者联合应用价值更高,血清BNP测值的转归预测价值更高。
文摘目的:观察益气通络化痰方联合达格列净治疗急性心肌梗死后心力衰竭的疗效及对心功能、血清脑钠肽(BNP)、心肌肌钙蛋白l(cTnl)水平的影响,以期为临床治疗提供可靠参考。方法:按照纳入和排除标准选用因急性心肌梗死入院时或住院期间出现心力衰竭的104例患者为研究对象,采集时间为2022年9月~2023年9月,按照随机数字表法将上述患者随机分为两组,即实验组与对照组,每组52例,其中对照组患者标准心力衰竭治疗(达格列净),实验组在标准治疗上加用益气通络化痰方。比较2组疗效,对其中医证候积分、心功能指标[心排出量(CO)、左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、血清指标[心房钠尿肽(ANP)、BNP、cTnl]的变化,并记录两组用药安全性及预后情况。结果:实验组总有效率为96.15%,而对照组总有效率为82.69%,两组相比差异有统计学意义( P <0.05);治疗后两组中医证候各项积分均较治疗前有不同程度的升高或降低( P <0.05),且治疗后相比,实验组LVESD、ANP、BNP、cTnl低于对照组( P <0.05),CO、LVEF、LVEDD高于对照组( P <0.05);实验组不良反应总发生率及因心衰再住院率分别为11.54%、5.77%,对照组分别为19.23%、19.23%,两组不良反应总发生率比较差异无统计学意义( P >0.05),但因心衰再住院率相比,差异有统计学意义( P <0.05)。结论:中医益气通络化痰方药联合达格列净用于急性心肌梗死后心力衰竭患者中疗效确切,不仅能有效恢复患者心功能作用,改善心室重构,还能调节ANP、BNP、cTnl等水平,抑制疾病进展,且预后良好,具有较大的临床应用价值。
